Drug Profile
Research programme: histone deacetylase inhibitors - Merck & Co
Alternative Names: ARQ-700RPLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 03 Sep 2007 Preclinical development is ongoing
- 05 Jul 2006 Preclinical trials in Cancer in USA (unspecified route)